Vanda Pharmaceuticals Inc. (VNDA): Net Income
-$220.47M
Year ended 2025-12-31
-$274.85M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$220.47M | n/m | 2026-02-12, From 2025-01-01 |
| 2024-12-31 | -$18.90M | n/m | 2026-02-12, From 2024-01-01 |
| 2023-12-31 | $2.51M | -60.0% | 2026-02-12, From 2023-01-01 |
| 2022-12-31 | $6.28M | -81.1% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $33.15M | +42.1% | 2024-02-08, From 2021-01-01 |
| 2020-12-31 | $23.34M | -79.8% | 2023-02-09, From 2020-01-01 |
| 2019-12-31 | $115.55M | +358.4% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $25.21M | n/m | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | -$15.57M | n/m | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | -$18.01M | n/m | 2019-02-19, From 2016-01-01 |
| 2015-12-31 | -$39.87M | n/m | 2018-02-15, From 2015-01-01 |
| 2014-12-31 | $20.19M | n/m | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | -$21.05M | n/m | 2016-02-12, From 2013-01-01 |
| 2012-12-31 | -$28.62M | n/c | 2015-03-13, From 2012-01-01 |
| 2011-12-31 | -$9.80M | n/m | 2014-02-25, From 2011-01-01 |
| 2010-12-31 | $7.19M | n/m | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | -$35.86M | n/a | 2012-03-09, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$220.47M | n/m |
| Amarin Corp PLC (AMRN) | 2025-12-31 | -$38.80M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$113.70M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $31.11M | +2.8% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | -$13.23M | n/m |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | -$5.34M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $87.01M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$196.54M | n/m |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$353.00M | n/m |
Compare VNDA, AMRN, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗